Oxford BioTherapeutics (OBT) has appointed Dr Michael Moore non-executive chairman. He joins the company following five years spent at UK …
Roche is set to pay $160 million (£315 million) to buy UK biotech company Piramed, a move which will further …
Piramed and Domainex are among the cutting-edge companies which have been recognised as the best of the UKs biotech sector.UK …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

